AEON Biopharma (AEON) vs Aspire-Lakewood (ASBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aspire-Lakewood (ASBP) has outperformed AEON Biopharma (AEON) over the past year, gaining 83.8% versus a loss of 85.2%. AEON Biopharma is the larger company by market cap ($10.3 million vs $10.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | ASBP |
|---|---|---|
| Share price | $0.123 | $7.13 |
| Market cap | $10.35M | $10.00M |
| 1-day change | -7.59% | -5.44% |
| YTD return | -88.82% | +35.04% |
| 1-year return | -85.18% | +83.76% |
| EPS (TTM) | $-3.89 | $-30.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.20K |
| Net income (latest FY) | $-39.22M | $-24.48M |
| Gross margin | — | -1.87% |
| Operating margin | — | -312016.95% |
| Net margin | — | -394725.06% |
| 52-week high | $1.45 | $9.50 |
| 52-week low | $0.106 | $0.11 |
| Distance from 52-week high | -91.52% | -24.95% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1379.67% | — |
| Average volume | 7.44M | 29.24K |
| Shares outstanding | 84.12M | 1.40M |
| Employees | 8 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASBP has outperformed AEON by 168.9 percentage points over the past year.
About AEON Biopharma
AEON stock →AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Aspire-Lakewood
ASBP stock →Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
Health Care · Biotechnology: Pharmaceutical Preparations
AEON vs ASBP FAQ
Which is bigger, AEON Biopharma or Aspire-Lakewood?
AEON Biopharma (AEON) is larger, with a market capitalization of $10.35M compared with $10.00M for Aspire-Lakewood (ASBP).
Which stock has performed better over the past year, AEON or ASBP?
ASBP returned +83.76% over the past 12 months, compared with -85.18% for AEON (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and Aspire-Lakewood in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.